Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Envafolimab - Alphamab Oncology/Ascletis/3D Medicine

Next Previous
X
Search
Drug Profile

Envafolimab - Alphamab Oncology/Ascletis/3D Medicine

Alternative Names: ASC 22; ENWEIDA; KN-035

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab Oncology
  • Developer 3D Medicines; Alphamab Oncology; Ascletis; Chipscreen Biosciences; Jiangsu Simcere Pharmaceutical; Sun Yat-Sen University; The First Affiliated Hospital of Xiamen University; TRACON Pharmaceuticals
  • Class Antibodies; Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Solid tumours
  • Phase III Biliary cancer; Non-small cell lung cancer
  • Phase II Endometrial cancer; Gastrointestinal cancer; Hepatitis B; HER2 positive breast cancer; HIV infections; Liver cancer; Malignant fibrous histiocytoma; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 01 Jul 2024 Efficacy data from a phase II ENVASARC trial for Malignant fibrous histiocytoma and Soft tissue sarcoma released by TRACON Pharmaceuticals
  • 01 Jul 2024 TRACON Pharmaceuticals terminates a phase II ENVASARC trial in Malignant fibrous histiocytoma and Soft tissue sarcoma in USA
  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Endometrial cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top